Where Will Hershey Stock Be In 1 Year?
Chocolate stocks used to be the epitome of sleepy stability,…
Sell
41
MIRA Quote, Financials, Valuation and Earnings
Last price:
$1.19
Seasonality move
:
49.27%
Day range:
$1.20 - $1.25
52-week range:
$0.51 - $5.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
16.21x
Volume:
15.3M
Avg. volume:
704K
1-year change:
105.74%
Market cap:
$21M
Revenue:
--
EPS (TTM):
-$0.51
Analysts' Opinion
-
Consensus RatingMira Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.75, Mira Pharmaceuticals has an estimated upside of 1331.45% from its current price of $1.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.75 representing -1331.45% downside risk from its current price of $1.24.
Fair Value
-
According to the consensus of 1 analyst, Mira Pharmaceuticals has 1331.45% upside to fair value with a price target of $17.75 per share.
MIRA vs. S&P 500
-
Over the past 5 trading days, Mira Pharmaceuticals has underperformed the S&P 500 by -1.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mira Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mira Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mira Pharmaceuticals reported revenues of --.
Earnings Growth
-
Mira Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mira Pharmaceuticals reported earnings per share of -$0.11.
Enterprise value:
19.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$6.9M | -$9M | -$8.1M | -$1.8M | -$1.8M | |
| EBITDA | -$6.9M | -$9M | -$8.1M | -$1.8M | -$1.8M | |
| Diluted EPS | -$0.41 | -$0.90 | -$0.51 | -$0.15 | -$0.11 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $251.1K | $3.7M | $1.4M | |
| Total Assets | -- | -- | $397.6K | $3.8M | $1.4M | |
| Current Liabilities | -- | -- | $2.1M | $652K | $106.2K | |
| Total Liabilities | -- | -- | $2.2M | $652K | $106.2K | |
| Total Equity | -- | -- | -$1.8M | $3.2M | $1.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.6M | -$4.5M | -$6.1M | -$1M | -$1.6M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $2.5M | $8M | $3.8M | -$24.3K | $3.4K | |
| Free Cash Flow | -$4.6M | -$4.5M | -$6.1M | -$1M | -$1.6M | |
MIRA
Sector
Market Cap
$21M
$33.7M
Price % of 52-Week High
24.75%
47.76%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
105.74%
-34.27%
Beta (5-Year)
--
0.625
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.23
200-day SMA
Buy
Level
$1.21
Bollinger Bands (100)
Buy
Level
0.99 - 1.29
Chaikin Money Flow
Buy
Level
61.3M
20-day SMA
Sell
Level
$1.26
Relative Strength Index (RSI14)
Sell
Level
49.62
ADX Line
Buy
Level
13.18
Williams %R
Neutral
Level
-52.6316
50-day SMA
Buy
Level
$1.23
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
355.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Stock Forecast FAQ
In the current month, MIRA has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MIRA average analyst price target in the past 3 months is $17.75.
-
Where Will Mira Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mira Pharmaceuticals share price will rise to $17.75 per share over the next 12 months.
-
What Do Analysts Say About Mira Pharmaceuticals?
Analysts are divided on their view about Mira Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mira Pharmaceuticals is a Sell and believe this share price will drop from its current level to $17.75.
-
What Is Mira Pharmaceuticals's Price Target?
The price target for Mira Pharmaceuticals over the next 1-year time period is forecast to be $17.75 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MIRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mira Pharmaceuticals is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of MIRA?
You can purchase shares of Mira Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mira Pharmaceuticals shares.
-
What Is The Mira Pharmaceuticals Share Price Today?
Mira Pharmaceuticals was last trading at $1.19 per share. This represents the most recent stock quote for Mira Pharmaceuticals. Yesterday, Mira Pharmaceuticals closed at $1.24 per share.
-
How To Buy Mira Pharmaceuticals Stock Online?
In order to purchase Mira Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will KNOT Stock Be In 1 Year?
In the case of KNOT Offshore Partners (KNOP), most headlines…
Why Is Goldman Sachs Stock Up So Much?
Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…
Stock Ideas
Buy
63
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 53x
Buy
60
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
92
BGL alert for Jul 3
Blue Gold [BGL] is down 20.3% over the past day.
Sell
18
CNC alert for Jul 3
Centene [CNC] is down 1.3% over the past day.
Sell
12
MOH alert for Jul 3
Molina Healthcare [MOH] is up 0.3% over the past day.
